101 liver cancer drug candidates pave the way to personalized medicine

The heart disease drug perhexiline is one of 101 compounds predicted to prevent cancer growth in most patients suffering from our most common liver cancer, HCC. This is an outcome from a novel simulation-based approach using personal sets of proteins of six HCC patients."This is the first time personalized models have been used to find and evaluate new potential drugs," says Professor Jens Nielsen at Chalmers University of Technology.Our most common liver cancer, Hepatocellular carcinoma, HCC, causes more than half a million deaths worldwide every year.

More...